Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11780839 Compounds for treating Huntington's disease

Patent 11780839 was granted and assigned to PTC Therapeutics, Inc. on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Current Assignee

PTC Therapeutics, Inc.

Date Filed

March 27, 2019

Date of Patent

October 10, 2023

Patent Applicant

PTC Therapeutics, Inc.

Patent Application Number

17040104

Patent Citations

‌

US Patent 7897792 Coumarin derivative having antitumor activity

‌

US Patent 7910578 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use

‌

US Patent 8143274 1-(2H)-isoquinolone derivative

‌

US Patent 8314119 Azaadamantane derivatives and methods of use

‌

US Patent 8337941 Fluorescent substrates for monoamine transporters as optical false neurotransmitters

‌

US Patent 8563550 Imidazolothiadiazoles for use as protein kinase inhibitors

‌

US Patent 8633019 Methods for treating spinal muscular atrophy

‌

US Patent 8846661 Diazahomoadamantane derivatives and methods of use thereof

‌

US Patent 8921361 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes

‌

US Patent 9371336 Compounds for treating spinal muscular atrophy

•••

Patent Inventor Names

Jigar S. Patel

Nicholas W. Mszar

Nadiya Sydorenko

Lukiana Amedzo

Nanjing Zhang

Anthony R. Mazzotti

Anuradha Bhattacharyya

Suresh Babu

Anthony Turpoff

Jana Narasimhan

•••

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11780839

Patent Primary Examiner

CPC Code

•••

Find more entities like US Patent 11780839 Compounds for treating Huntington's disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.